Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

In the last week, the United States market has stayed flat, yet it has risen by 30% over the past year with earnings ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta has overcome a major regulatory obstacle and now plans to file its Duchenne Muscular Dystrophy treatment with the FDA by the end of 2014. The US company had received a major blow when the ...